Table 1.
Patient characteristics
| No. of patients (n = 43) | |
|---|---|
| Age at diagnosis (years)* | 64·6(8·9) |
| Sex ratio (M : F) | 31 : 12 |
| Site of primary tumour | |
| Colon | 31 |
| Rectum | 12 |
| Liver metastases | |
| No. per patient* | 6·6(5·4) |
| Synchronous | 30 |
| Metachronous | 13 |
| Solitary | 9 |
| Bilobar | 30 |
| Initially resectable disease | 22 |
| Initially unresectable disease | 21 |
| Portal vein embolization | 9 |
| Concurrent extrahepatic metastasis | 9 |
| Initial imaging evaluation | |
| MRI + CT + (CE)US + PET | 2 |
| MRI + CT + (CE)US | 30 |
| MRI + CT | 6 |
| CT + (CE)US | 5 |
| Preoperative chemotherapy regimen | |
| FOLFOX | 15 |
| FOLFOX + bevacizumab | 8 |
| FOLFOX + anti‐EGFR | 4 |
| FOLFIRI + bevacizumab | 3 |
| FOLFIRI + anti‐EGFR | 6 |
| FOLFIRI | 1 |
| FOLFIRINOX | 2 |
| Capecitabine | 4 |
| No. of cycles before hepatic treatment† | 4·6(1·4) |
Values are *mean(s.d.) and †mean(s.d.) based on 37 patients (6 patients with 14 marked metastases were excluded because of progression). (CE)US, (contrast‐enhanced) ultrasonography; PET, positron emission tomography; EGFR, epidermal growth factor receptor.